Development of a novel ovarian cancer molecular target therapy against cancer-related transcriptional factor, NAC1

Journal of Obstetrics and Gynaecology Research

Volumn 39, Issue 1, 2013, Pages 18-25

  Nakayama, Kentaro ^a   Nakayama, Naomi ^a   Miyazaki, Kohji ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HOMODIMER; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NAC1; UNCLASSIFIED DRUG; UVOMORULIN;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER RESISTANCE; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; COMPARATIVE GENOMIC HYBRIDIZATION; CRYSTAL STRUCTURE; CRYSTALLIZATION; DELETION MUTANT; DIMERIZATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KARYOTYPING; MALIGNANT TRANSFORMATION; METASTASIS; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PROGRESSION FREE SURVIVAL; TRANSGENIC MOUSE;

FEMALE; HUMANS; KARYOTYPING; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; REPRESSOR PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84866923065     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2012.01946.x     Document Type: Article

References (23)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995; 45: 8-30.
2. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008; 68: 3077-3080.
3. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
4. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
5. Nakayama K, Nakayama N, Davidson B et al. A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci USA 2006; 103: 18739-18744.
6. Shih Ie M, Nakayama K, Wu G et al. Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma. Mod Pathol 2011; 24: 638-645.
7. Ishibashi M, Nakayama K, Yeasmin S et al. A BTB/POZ gene, NAC-1, a tumor recurrence-Associated gene, as a potential target for Taxol resistance in ovarian cancer. Clin Cancer Res 2008; 14: 3149-3155.
8. Nakayama K, Rahman MT, Rahman M et al. Biological role and prognostic significance of NAC1 in ovarian cancer. Gynecol Oncol 2010; 119: 469-478.
9. Wang TL, Maierhofer C, Speicher MR et al. Digital karyotyping. Proc Natl Acad Sci USA 2002; 99: 16156-16161.
10. Shih Ie M, Sheu JJ, Nakayama K et al. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci USA 2005; 102: 14004-14009.
11. Park JT, Li M, Nakayama K et al. Notch3 gene amplification in ovarian cancer. Cancer Res 2006; 66: 6312-6318.
12. Nakayama K, Nakayama N, Jinawath N et al. Amplicon profiles in ovarian serous carcinomas. Int J Cancer 2007; 120: 2613-2617.
13. Cho KR, Shih Ie M. Ovarian cancer. Annu Rev Pathol 2009; 4: 287-313.
14. Davidson B, Berner A, Trope CG et al. Expression and clinical role of the bric-A-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions. Hum Pathol 2007; 38: 1030-1036.
15. Fujiwara T, Bandi M, Nitta M et al. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 2005; 437: 1043-1047.
16. Jinawath N, Vasoontara C, Yap KL et al. NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway. Oncogene 2009; 28: 1941-1948.
17. Zhang Y, Cheng Y, Ren X et al. NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response. Oncogene 2012; 31: 1055-1064.
18. Yeasmin S, Nakayama K, Ishibashi M et al. Expression of the bric-A-brac tramtrack broad complex protein NAC-1 in cervical carcinomas seems to correlate with poorer prognosis. Clin Cancer Res 2008; 14: 1686-16891.
19. Yeasmin S, Nakayama K, Rahman MT et al. Biological and clinical significance of NAC1 expression in cervical carcinomas: A comparative study between squamous cell carcinomas and adenocarcinomas/adenosquamous carcinomas. Hum Pathol 2012; 43: 506-519.
20. Nakayama K, Nakayama N, Wang TL et al. NAC-1 controls cell growth and survival by repressing transcription of Gadd45GIP1, a candidate tumor suppressor. Cancer Res 2007; 67: 8058-8064.
21. Ueda SM, Yap KL, Davidson B et al. Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas. J Oncol 2010; 2011: 1-12.
22. Yeasmin S, Nakayama K, Rahman MT et al. Loss of MKK4 expression in ovarian cancer: A potential role for the epithelial to mesenchymal transition. Int J Cancer 2011; 128: 94-104.
23. Stead MA, Carr SB, Wright SC. Structure of the human Nac1 POZ domain. Acta Crystallogr Sect F Struct Biol Cryst Commun 2009; 65: 445-449.